Clinical Trials Logo

Clinical Trial Summary

Catastrophic is defined as a negative cognitive and emotional response based on inadequate pain expression. It has three components: rumination, amplification and vulnerability. The assessment of catastrophism is carried out using a validated questionnaire called the "Pain Catatrophizing Scale" (PCS). Recent studies highlight the significant impact of catastrophism in neuromuscular and mechanical rheumatic diseases such as gonarthrosis gonalgia and low back pain. In these diseases, it has been shown that catastrophism has a negative impact both on the experience of pain and on the response to different types of treatments (medical and surgical). Several studies have implemented multidisciplinary management and in particular cognitive-behavioural therapy with an improvement in the pain experience in patients who are catastrophic. In chronic inflammatory rheumatic diseases such as rheumatoid arthritis, spondyloarthritis and psoriatic arthritis, the prevalence and impact of catastrophism is still poorly understood.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04174092
Study type Interventional
Source Centre Hospitalier Universitaire de Nimes
Contact
Status Completed
Phase N/A
Start date October 27, 2019
Completion date December 17, 2022

See also
  Status Clinical Trial Phase
Completed NCT04530682 - COVID-19 in Rheumatic Inflammatory Diseases Under Immuno-suppressive Drugs
Not yet recruiting NCT04749875 - Study of Leukocyte Populations in Patients With Chronic Inflammatory
Not yet recruiting NCT05026892 - Identification of Factors Associated With the Occurrence of Severe Forms of COVID-19 Infection in Patients With Inflammatory Rheumatism or Autoimmune Diseases
Recruiting NCT04353609 - Covid-19 in Patients With Chronic Inflammatory Rheumatism, Auto-immune or Auto-inflammatory Rare and Non-rare Diseases